FLGT

Nohaile Michael

Known title: DirectorCIK: 0001890563

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 25, 2026

FLGT compared to PRPO in cancer diagnostics sector. A recent article compares Fulgent Genetics with PrecisionDx, evaluating which cancer diagnostics stock has more potential. This comparison highlights FLGT's position within the specialized diagnostics market. The stock is currently trading near the average analyst target price of $19.00, which sits within its 52-week range.

this person other insiders at FLGT

Transaction History

FLGT▲ Buy$0
FLGT▲ Buy$0
FLGT▲ Buy$0
FLGT▲ Buy$0
FLGT▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.